Steps to complete the survey:
1. Click on Sign In button and login/register from your account.
2. Click on Participate button, and you will be directed to the survey page.
3. Fill in the survey and submit.
4. Please fill out the bank details after submitting the survey
Increased cardiovascular (CV) mortality is one of the features of CKD Together, deaths due to CKD or to CKD-attributable CVD accounted for 4.6% of all-cause mortality.
Hence it becomes imperative to select drugs that can reduce CV events and thereby improve overall health in CKD patients. Further CKD-associated conditions like Anemia, uremic pruritis need to be evaluated and managed as they can significantly impact the overall quality of life.
As evidenced from multiple trials that sodium–glucose co-transporter-2 (SGLT2) inhibitors demonstrate nephroprotection as well as proven to be cardioprotective. Another new important therapeutic drug offering better composite kidney outcomes is a novel non-steroidal, selective mineralocorticoid-receptor antagonist (MRA). It has received approval for use of cardiorenal protection in diabetic CKD patients.
Other important areas include newer therapies for managing anemia, therapies for uremic pruritis to improve quality of life and for lupus nephritis.
A simple questionnaire based on the clinical perspective in diabetic and non-diabetic CKD patients has been created and the detailed report of outcomes shall be calibrated based on the survey.
This survey information can be used in further evaluating the needs and deciding on an appropriate therapeutic regimen in the best interest of the patient.
Survey objectives:
1. To derive an unbiased approach in decision making
2. To collect perceptions, opinions, and comments from Nephrologists and understand gaps in therapy.
3. To establish best treatment strategies in diabetic and non-diabetic CKD patients.
4. By analysing results, to address the topics of importance
Target audience:
Nephrologists and Consulting physicians